Fomepizole is always administered by a healthcare professional in a hospital or critical care setting. It is given as an intravenous (IV) infusion.

• Preparation: Fomepizole typically comes in a concentrated solution and must be diluted with sterile 0.9% sodium chloride injection or dextrose 5% injection before administration. It should never be given undiluted or as a direct bolus injection.
  
  
• Administration Rate: The diluted solution is infused slowly over a specific period, usually 30 minutes.
  
  
• Dosage Regimen: A loading dose is given first, followed by maintenance doses at regular intervals (e.g., every 12 hours). The dosage and frequency may need to be adjusted, especially if the patient is undergoing hemodialysis, as hemodialysis effectively removes fomepizole from the body.
  
  
• Monitoring: Patients receiving fomepizole are continuously monitored, with frequent blood tests (for ethylene glycol or methanol levels, acid-base status, kidney function) and vital sign checks. Treatment continues until the toxic alcohol levels are below a safe threshold and metabolic abnormalities are corrected.
  
  
• Polycarbonate Syringes/Needles: It is crucial not to use polycarbonate syringes or needles containing polycarbonate filters when preparing or administering fomepizole, as the drug can interact with polycarbonate, potentially compromising the integrity of the syringe/needle.
  
  
• Administration: IV infusion, always by a healthcare professional.
  
  
• Dilution: Must be diluted before administration (not given neat or as a bolus).
  
  
• Dosing: Loading dose followed by maintenance doses; adjusted for hemodialysis.
  
  
• Monitoring: Continuous blood tests and vital sign monitoring.
  
  

Special Note: Avoid polycarbonate-containing syringes/needles.

The toxicity of ethylene glycol and methanol doesn’t come from the parent compounds themselves, but from the highly toxic metabolites they are converted into in the body. This conversion process is catalyzed by an enzyme called alcohol dehydrogenase (ADH).

Fomepizole works as a competitive inhibitor of alcohol dehydrogenase. This means it binds to the ADH enzyme much more strongly than ethylene glycol or methanol do. By occupying the active site of ADH, fomepizole effectively blocks the enzyme from metabolizing ethylene glycol into toxic glycoaldehyde (which further breaks down into glycolic acid and oxalic acid) or methanol into toxic formaldehyde (which then breaks down into formic acid). These toxic metabolites are responsible for the severe metabolic acidosis, kidney damage (from ethylene glycol), and visual disturbances or blindness (from methanol) seen in poisoning cases. By preventing their formation, fomepizole allows the parent alcohols to be safely excreted from the body, often via the kidneys, before they can be converted into harmful substances.

• Mechanism: Competitive inhibitor of alcohol dehydrogenase (ADH).
• Action: Blocks the metabolism of ethylene glycol and methanol into their toxic byproducts.
• Result: Prevents severe metabolic acidosis, organ damage (kidney), and visual impairment/blindness.
• Outcome: Allows safe excretion of parent alcohols from the body.

While fomepizole is critical in life-threatening poisoning, it can still cause side effects. These are typically monitored and managed in the hospital setting.

• Common Side Effects (often mild to moderate):
  • Headache
  • Nausea and Vomiting
  • Dizziness or Lightheadedness
  • Drowsiness
  • Bad or Metallic Taste in mouth
  • Injection site reactions (e.g., irritation, pain, inflammation of the vein)
  • Mild skin rash or itching
• Less Common or More Serious Side Effects:
  • Allergic reactions: Though rare, severe allergic reactions (e.g., hives, difficulty breathing, swelling of the face/throat) can occur and require immediate medical attention.
  • Transient elevations in liver function tests (AST/ALT).
  • Changes in vision, smell, or taste (less common than those caused by the poisons themselves, but possible).
  • Nystagmus (involuntary eye movements).

It’s important to note that many symptoms experienced during treatment might be due to the underlying poisoning itself, rather than the fomepizole.

• Common: Headache, nausea/vomiting, dizziness, drowsiness, metallic taste, injection site reactions.
• Serious (Rare): Allergic reactions, transient liver enzyme elevations.
• Note: Some symptoms may be from the poisoning, not the antidote.

Due to the critical nature of its use, specific warnings and precautions are paramount with fomepizole.

• Hypersensitivity: Fomepizole is contraindicated in patients with a known severe allergy to fomepizole or other pyrazoles (a class of chemicals). However, in a life-threatening poisoning, the benefit may outweigh the risk of a mild allergic reaction.
  
  
• Liver and Kidney Function: Patients with pre-existing liver or kidney problems should be monitored closely, as these organs are crucial for eliminating both the poisons and fomepizole itself. Dosage adjustments may be necessary for patients with renal impairment or those on hemodialysis.
  
  
• Polycarbonate Interaction: As mentioned, fomepizole can interact with polycarbonate plastics. It’s critical to avoid polycarbonate syringes, filter needles, or other administration equipment containing polycarbonate to prevent compromise of the device.
  
  
• Pregnancy and Breastfeeding: Animal reproduction studies have not been conducted, and it’s unknown if fomepizole can cause fetal harm or is excreted in human milk. In emergency situations, the decision to use fomepizole in pregnant or breastfeeding women is made by the medical team based on a critical risk-benefit assessment, as the poisoning itself poses a severe threat.
  
  
• Fluid and Electrolyte Balance: Patients with ethylene glycol or methanol poisoning often have severe metabolic acidosis and electrolyte imbalances, which need to be aggressively managed alongside fomepizole administration.
  
  
• Contraindication: Known severe allergy to fomepizole or other pyrazoles.
  
  
• Monitoring: Close monitoring of liver/kidney function, fluid, and electrolytes.
  
  
• Equipment: Do not use polycarbonate-containing administration sets.
  
  

Pregnancy/Lactation: Use with caution, only if clearly needed, in critical situations.

Given that fomepizole is primarily used in acute poisoning emergencies, specific drug interactions are carefully managed by the medical team. However, some general considerations exist:

• Ethanol (Alcohol): Both fomepizole and ethanol are substrates for alcohol dehydrogenase. In the past, ethanol infusions were used as an antidote for ethylene glycol and methanol poisoning because ethanol has a higher affinity for ADH. However, fomepizole has a significantly higher affinity for ADH than ethanol, making it a superior and safer antidote. Therefore, if fomepizole is being used, concomitant ethanol administration is generally unnecessary and can even complicate management by adding ethanol’s own toxic effects. Fomepizole also decreases the elimination of ethanol, potentially prolonging its effects.
• Drugs Metabolized by the Cytochrome P450 System: Fomepizole can induce (speed up) or inhibit (slow down) the metabolism of other drugs that are processed by the cytochrome P450 enzyme system in the liver. This can potentially alter the levels of co-administered medications, though in an acute poisoning setting, the focus is on the immediate crisis.
• Drugs Affecting Renal Excretion: Some drugs that affect kidney function or excretion pathways could theoretically alter fomepizole’s elimination, but this is managed clinically.

Always ensure the medical team treating the poisoning is aware of any and all medications the patient was taking prior to the emergency.

• Primary Consideration: Interaction with ethanol (both target ADH; fomepizole is preferred).
• Enzyme Induction/Inhibition: Can affect metabolism of other drugs via cytochrome P450.
• Clinical Management: Interactions are carefully managed by medical professionals in an acute care setting.

Fomepizole dosage is specific and managed by medical professionals in an acute care setting. It is not a drug for self-administration.

• Initial Loading Dose: Typically, 15 mg/kg body weight, administered intravenously over 30 minutes.
  
  
• Maintenance Doses: Following the loading dose, subsequent doses of 10 mg/kg are given every 12 hours for four doses.
  
  
• Increased Dose (after 4 doses): If treatment is required beyond four maintenance doses, the dose is increased to 15 mg/kg every 12 hours because fomepizole induces its own metabolism, leading to faster elimination.
  
  
• Dosing During Hemodialysis: If the patient is undergoing hemodialysis, the frequency of fomepizole administration needs to be significantly increased (e.g., to every 4 hours), as hemodialysis effectively removes fomepizole from the bloodstream. Specific guidelines apply for dosing at the start, during, and after dialysis sessions.
  
  
• Duration of Treatment: Fomepizole should be continued until ethylene glycol or methanol concentrations are undetectable or have fallen below a critical threshold (e.g., less than 20 mg/dL), and the patient’s acid-base status is normalized.
  
  
• Initial Dose: 15 mg/kg IV over 30 minutes (loading).
  
  
• Maintenance: 10 mg/kg IV q12h for 4 doses, then 15 mg/kg IV q12h.
  
  
• Dialysis Adjustment: Increased frequency (e.g., q4h) during hemodialysis.
  
  

Endpoint: Continue until toxic alcohol levels are safe and acid-base status is normal.

Fomepizole is a prescription-only medication that is not available to the general public for purchase or self-administration.

The strict prescription requirement is due to:

• Emergency Use: It is an antidote for life-threatening poisonings and must be administered promptly in a controlled medical environment.
  
  
• Complex Administration: It requires intravenous administration, specific dilution, and precise dosing adjustments based on the patient’s clinical status and laboratory values.
  
  
• Severe Underlying Condition: It treats severe poisoning that can rapidly lead to organ damage or death without immediate intervention.
  
  
• Professional Oversight: The decision to use fomepizole, its dosage, duration, and concomitant treatments (like hemodialysis) require the expertise and continuous monitoring of a trained medical team, usually in an intensive care or emergency department setting.
  
  
• Status: Prescription-only medication.
  
  
• Availability: Not for public purchase; administered only in medical facilities.
  
  
• Rationale: Critical emergency use, complex administration, severe underlying conditions, and need for continuous professional oversight.

1. What is Fomepizole used for? Treatment of methanol or ethylene glycol poisoning.

2. What drug class does it belong to? Antidotes; alcohol dehydrogenase inhibitor.

3. What is the active ingredient? Fomepizole (4-methylpyrazole).

4. What strengths are available? 1 g/mL solution for intravenous injection.

5. How is it administered? IV infusion, often in a hospital setting; may be combined with hemodialysis.

6. What is the usual dosage?

• Initial: 15 mg/kg IV over 30 minutes

• Then: 10 mg/kg every 12 hours for 4 doses

• Then: 15 mg/kg every 12 hours until levels normalize

7. What are common side effects? Headache, nausea, dizziness, metallic taste, and injection site reactions.

8. Can it cause serious reactions? Rare—allergic reactions, skin rash, bruising, or neuropathy.

9. Is it safe during pregnancy? Use only if clearly needed; limited human data.

10. Is a prescription required? Yes, administered under emergency medical supervision.

11. Is it available in Pakistan? Rare; may be imported for emergency use in tertiary hospitals.

12. How does it work? Blocks alcohol dehydrogenase, preventing conversion of methanol/ethylene glycol into toxic metabolites.

13. What are alternatives to Fomepizole? Ethanol (IV or oral) is a traditional alternative antidote.

14. Is it used for ethanol overdose? No—only for methanol and ethylene glycol toxicity.

15. What monitoring is needed during use? Serum methanol/ethylene glycol levels, renal function, acid-base status.

16. Is it used in children? Yes, with weight-based dosing.

17. What is the onset of action? Rapid—within minutes of IV administration.

18. What precautions should be taken? Avoid alcohol; monitor for CNS symptoms and metabolic acidosis.

19. What is the chemical formula? C₄H₆N₂ (4-methylpyrazole).

20. What is the FDA approval status? Approved for treatment of confirmed or suspected methanol/ethylene glycol poisoning.